CZ281353B6 - Léčivo pro aplikaci při odmítavých reakcích organismu při transplantacích orgánů - Google Patents

Léčivo pro aplikaci při odmítavých reakcích organismu při transplantacích orgánů Download PDF

Info

Publication number
CZ281353B6
CZ281353B6 CS922582A CS258292A CZ281353B6 CZ 281353 B6 CZ281353 B6 CZ 281353B6 CS 922582 A CS922582 A CS 922582A CS 258292 A CS258292 A CS 258292A CZ 281353 B6 CZ281353 B6 CZ 281353B6
Authority
CZ
Czechia
Prior art keywords
compound
manufacture
formula
organism
administration
Prior art date
Application number
CS922582A
Other languages
Czech (cs)
English (en)
Inventor
Robert Ryder Dr. Bartlett
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of CZ258292A3 publication Critical patent/CZ258292A3/cs
Publication of CZ281353B6 publication Critical patent/CZ281353B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
CS922582A 1991-08-22 1992-08-21 Léčivo pro aplikaci při odmítavých reakcích organismu při transplantacích orgánů CZ281353B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4127737A DE4127737A1 (de) 1991-08-22 1991-08-22 Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen

Publications (2)

Publication Number Publication Date
CZ258292A3 CZ258292A3 (en) 1993-03-17
CZ281353B6 true CZ281353B6 (cs) 1996-09-11

Family

ID=6438804

Family Applications (1)

Application Number Title Priority Date Filing Date
CS922582A CZ281353B6 (cs) 1991-08-22 1992-08-21 Léčivo pro aplikaci při odmítavých reakcích organismu při transplantacích orgánů

Country Status (18)

Country Link
US (3) US5728721A (enExample)
EP (1) EP0529500B1 (enExample)
JP (1) JP3285226B2 (enExample)
KR (1) KR100253450B1 (enExample)
AT (1) ATE113835T1 (enExample)
AU (1) AU654031B2 (enExample)
CA (1) CA2076555C (enExample)
CZ (1) CZ281353B6 (enExample)
DE (2) DE4127737A1 (enExample)
DK (1) DK0529500T3 (enExample)
ES (1) ES2065738T3 (enExample)
HU (1) HU219402B (enExample)
IL (1) IL102886A (enExample)
MX (1) MX9204875A (enExample)
RU (1) RU2067862C1 (enExample)
SK (1) SK279323B6 (enExample)
TW (1) TW210284B (enExample)
ZA (1) ZA926310B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
PT787491E (pt) * 1994-10-17 2000-11-30 Aventis Pharma Ltd Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
DE19857009A1 (de) * 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
WO2003039231A2 (en) * 2001-10-25 2003-05-15 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2005011669A1 (ja) * 2003-08-05 2005-02-10 Dainippon Sumitomo Pharma Co., Ltd. 経皮投与用医薬組成物
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
DE102005017592A1 (de) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436263C2 (de) 1974-07-27 1983-02-17 Hoechst Ag, 6000 Frankfurt Thiazolidinderivate und Verfahren zu ihrer Herstellung
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
GB8320969D0 (en) * 1983-08-03 1983-09-07 Ici Plc Transparent sheet
DE3405727A1 (de) 1984-02-17 1985-08-22 Hoechst Ag, 6230 Frankfurt Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
DE4101324A1 (de) 1991-01-18 1992-07-23 Hoechst Ag Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
EP0538783B1 (de) 1991-10-23 1995-09-27 Hoechst Aktiengesellschaft N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
US6223209B1 (en) * 1997-09-30 2001-04-24 Ncr Corporation Distributed world wide web servers

Also Published As

Publication number Publication date
SK258292A3 (en) 1995-09-13
SK279323B6 (sk) 1998-10-07
EP0529500A1 (de) 1993-03-03
EP0529500B1 (de) 1994-11-09
US20050080118A1 (en) 2005-04-14
HUT64845A (en) 1994-03-28
KR930003915A (ko) 1993-03-22
JPH05208909A (ja) 1993-08-20
HU219402B (hu) 2001-04-28
US6288098B1 (en) 2001-09-11
JP3285226B2 (ja) 2002-05-27
DE4127737A1 (de) 1993-02-25
TW210284B (enExample) 1993-08-01
AU654031B2 (en) 1994-10-20
ZA926310B (en) 1993-04-28
DE59200773D1 (de) 1994-12-15
CZ258292A3 (en) 1993-03-17
ES2065738T3 (es) 1995-02-16
US5728721A (en) 1998-03-17
CA2076555A1 (en) 1993-02-23
MX9204875A (es) 1993-02-01
US7402601B2 (en) 2008-07-22
AU2124792A (en) 1993-02-25
RU2067862C1 (ru) 1996-10-20
CA2076555C (en) 2003-07-29
KR100253450B1 (ko) 2000-07-01
DK0529500T3 (da) 1995-04-18
ATE113835T1 (de) 1994-11-15
IL102886A0 (en) 1993-01-31
IL102886A (en) 1996-01-19

Similar Documents

Publication Publication Date Title
CZ258292A3 (en) Medicament to be applied in cases of organism rejecting reactions to transplanted organs
US4968701A (en) 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
JPH05507697A (ja) 臓器移植拒絶反応の治療
JPH0662407B2 (ja) 安定化された３―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤
SK319892A3 (en) N-phenyl-2-cyano-3-hydroxycrotonamide derivatives, method of their poduction and their using for manufacture of medicines with immunomodulating effect
US6133301A (en) Pharmaceuticals for the treatment of rejection reactions in organ transplantations
JPS63201187A (ja) ４−チアゾリジンカルボン酸誘導体、その製造法および医薬品組成物
EP0617959A1 (en) Pharmaceutical for the treatment of skin disorders
EP0290817B1 (en) A use of oxetanocin for inhibiting hiv
JPH025735B2 (enExample)
US4654333A (en) Treatment of multiple sclerosis
US5503830A (en) Compounds having immunostimulating activity and methods of use thereof
US4419367A (en) Stimulant
LT3589B (en) Using of known combination for treatment of rejection reaction by transplantation of organs
CA3157631A1 (en) Use of compound in preventing or treating graft versus host disease
US20240197816A1 (en) Composition and method for prolong survival of transplant and recipient
US3862061A (en) Imidazole derivatives
JPS61126026A (ja) イソキノリンスルホン酸アミドを有効成分とする抗癌剤
US10343997B1 (en) Ursolic acid derivatives
JPS61134312A (ja) 移植免疫抑制剤並びに抗アレルギ−剤
JPS5930682B2 (ja) 家畜の代謝性疾患の予防および治療方法
WO1994028892A1 (en) Inhibitor for rejection accompanying organ transplantation
JPH0959260A (ja) チアミンジスルフィド類及びこれを有効成分とする医薬

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20120821